Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today.

Yaron Werber has given his Buy rating due to a combination of factors, chiefly the strong Phase 2 results for verekitug in asthma and chronic rhinosinusitis with nasal polyps, where the drug matched or exceeded leading competitors while requiring far less frequent quarterly dosing. He views the planned single high-dose 400 mg every-12-weeks regimen, delivered via autoinjector across broad patient groups, as a clinically and commercially attractive profile that aligns with physician preferences without compromising efficacy.

Werber also highlights meaningful catalysts and a solid financial runway, including Phase 3 trial launches in early 2027, an advancing COPD Phase 2 study with significant upside, and cash resources that extend into 2027, reducing near-term financing risk. In his view, verekitug’s developmental lead, differentiated dosing schedule, and the large addressable markets in asthma, COPD, and CRSwNP position it as a potential blockbuster, leaving competitors under pressure to prove comparable long-interval regimens that are not yet de-risked.

Werber covers the Healthcare sector, focusing on stocks such as Amgen, Ionis Pharmaceuticals, and Ultragenyx Pharmaceutical. According to TipRanks, Werber has an average return of 23.3% and a 58.75% success rate on recommended stocks.

In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $42.00 price target.